What is Exsure?
Founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure is pioneering an exosomal drug-delivery platform designed to mitigate the severe side-effects and toxicity associated with traditional anti-cancer therapies. This innovative technology targets both primary tumors and cancer-stem cells, aiming to enhance patient quality of life by reducing the debilitating effects of chemotherapy and lowering the risk of cancer recurrence. Exsure's approach represents a significant advancement in personalized oncology, addressing critical unmet needs in cancer treatment.
How much funding has Exsure raised?
Exsure has raised a total of $351K across 1 funding round:
Angel/Seed
$351K
Angel/Seed (2025): $351K with participation from Unicorn India Ventures
Key Investors in Exsure
Unicorn India Ventures
Unicorn India Ventures is a venture capital firm specializing in seed funding for startups, with a focus on early-stage impactful innovations and technology-driven solutions. They provide capital, mentorship, and operational support to help portfolio companies achieve sustainable growth and societal impact.
What's next for Exsure?
The substantial backing from its recent funding round, characterized as a large-scale late-stage funding event, positions Exsure for accelerated growth and the scaling of its patented technology. This strategic investment is expected to fuel further research and development, clinical trials, and the potential commercialization of its exosomal drug-delivery system. The company's focus on reducing toxicity and relapse signifies a commitment to improving patient outcomes, a critical factor in the evolving biotech sector.
See full Exsure company page
